Verdonck Kristien, González Elsa, Van Dooren Sonia, Vandamme Anne-Mieke, Vanham Guido, Gotuzzo Eduardo
Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.
Lancet Infect Dis. 2007 Apr;7(4):266-81. doi: 10.1016/S1473-3099(07)70081-6.
Human T-lymphotropic virus 1 (HTLV-1) has infected human beings for thousands of years, but knowledge about the infection and its pathogenesis is only recently emerging. The virus can be transmitted from mother to child, through sexual contact, and through contaminated blood products. There are areas in Japan, sub-Saharan Africa, the Caribbean, and South America where more than 1% of the general population is infected. Although the majority of HTLV-1 carriers remain asymptomatic, the virus is associated with severe diseases that can be subdivided into three categories: neoplastic diseases (adult T-cell leukaemia/lymphoma), inflammatory syndromes (HTLV-1-associated myelopathy/tropical spastic paraparesis and uveitis among others), and opportunistic infections (including Strongyloides stercoralis hyperinfection and others). The understanding of the interaction between virus and host response has improved markedly, but there are still no clear surrogate markers for prognosis and there are few treatment options.
人类嗜T淋巴细胞病毒1型（HTLV-1）已经感染人类数千年，但有关这种感染及其发病机制的知识直到最近才逐渐显现。该病毒可通过母婴传播、性接触以及受污染的血液制品传播。在日本、撒哈拉以南非洲、加勒比地区和南美洲的一些地区，超过1%的普通人群受到感染。尽管大多数HTLV-1携带者仍无症状，但该病毒与严重疾病有关，这些疾病可分为三类：肿瘤性疾病（成人T细胞白血病/淋巴瘤）、炎症综合征（HTLV-1相关脊髓病/热带痉挛性截瘫以及葡萄膜炎等）和机会性感染（包括粪类圆线虫高度感染等）。对病毒与宿主反应之间相互作用的理解有了显著提高，但仍然没有明确的预后替代标志物，治疗选择也很少。
